{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"To determine the molecular signatures of response and resistance to amivantamab via molecular signatures of response and resistance- measured by comprehensive analysis of Transcriptome Sequencing","groups":[{"description":"Amivantamab weekly for the first cycle and biweekly thereafter.\n\nAmivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).","id":"OG000","title":"Amivantamab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Of the available data, the number of subjects with a genetic mutation were reported.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With a Genetic Mutation","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}